Immupharma PLC Notice of AGM & Annual Report & Accounts
June 05 2024 - 9:01AM
RNS Regulatory News
RNS Number : 2666R
Immupharma PLC
05 June 2024
RNS:
RELEASE
5 June 2024
ImmuPharma
PLC
("ImmuPharma" or the "Company")
Notice of AGM & Annual
Report & Accounts
ImmuPharma PLC (LSE AIM: IMM), the
specialist drug discovery and development company, is pleased to
confirm that the Company's Annual General Meeting ("AGM") will be
held on Friday 28 June 2024 @ 11:00a.m. (BST), at the offices of
Evelyn Partners, 45 Gresham Street, London,
EC2V 7BG.
The Notice of AGM setting out
details of the resolutions, together with the Company's Annual
Report and Accounts for the year ended 31 December 2023, has been
posted to those shareholders requesting a postal copy; and for
other shareholders, these documents will shortly be available to
view and download on the Company's website:
www.immupharma.co.uk.
Ends
|
For further information please
contact:
|
ImmuPharma PLC (www.immupharma.co.uk)
Tim McCarthy, Chairman and Chief
Executive Officer
|
+ 44 (0) 207 206 2650
|
|
Lisa Baderoon, Head of Investor
Relations
|
+ 44 (0) 7721 413496
|
|
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin
Stanford Capital Partners (Joint Broker)
Patrick Claridge, Bob
Pountney
SI
Capital (Joint Broker)
Nick Emerson
|
+44 (0) 203
368
3550
+44 (0) 203 815 8880
+44 (0) 1483 413500
|
|
|
|
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a
specialty biopharmaceutical company that discovers and develops
peptide-based therapeutics. The Company's portfolio includes novel
peptide therapeutics for autoimmune diseases and anti-infectives.
The lead program, P140 is a first-in class autophagy
immunomodulator for the treatment of Lupus and CIDP and preclinical
analysis suggests P140 may have therapeutic benefit in many other
autoimmune diseases that are caused by the same dysfunction in the
immune system.
For additional information about
ImmuPharma please visit: www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity
Identifier) code : 213800VZKGHXC7VUS895.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
ACSLELFBZQLEBBK
Immupharma (LSE:IMM)
Historical Stock Chart
From Oct 2024 to Nov 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Nov 2023 to Nov 2024
